The veteran medical devices industry executive pointed to miniaturization, minimally invasive surgery, navigation and remote steering, minimize hospitalization, multimodality imaging, drug and device hybrids, and gene and cell therapy, as the main trends for biotech products worldwide, including in Israel.

With the soaring costs of research and development, young Israeli companies with “insufficient funding” can first turn to the central government, which has set up 200 “incubators” aim at gathering pre-startups around biotech clusters, she explained.

Once the project in more mature, Nir stressed that venture funds will more easily consider investing in innovative technology such as new cardiology treatments or cutting-edge robotic surgical systems.

Since 1992, Giza has invested in 87 leading technology companies in various sectors, she noted. The company reportedly manages four funds totaling US$500 million.

Given Taiwan’s strong Information Technology (IT) sector, she suggested that Taiwanese government jump on the biotech bandwagon and preemptively support local biotech managers and researchers.

Subscribe to The China Post and save.  Click hereSharePrintEmail

Write a Comment

Enter your comments - 800 characters max

Receive China Post promos

Respond to this email